Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VIROPTIC vs AVASTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Trifluridine is a fluorinated pyrimidine nucleoside analogue that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase.
Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.
Treatment of keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus types 1 and 2
Metastatic colorectal cancer (first- or second-line in combination with intravenous 5-fluorouracil-based chemotherapy),Non-small cell lung cancer (first-line in combination with carboplatin and paclitaxel for unresectable, locally advanced, recurrent or metastatic non-squamous disease),Glioblastoma (single agent for progressive disease following prior therapy),Metastatic renal cell carcinoma (in combination with interferon alfa),Ovarian epithelial, fallopian tube, or primary peritoneal cancer (in combination with paclitaxel and carboplatin or pegylated liposomal doxorubicin for platinum-sensitive recurrent disease; as a single agent for platinum-resistant recurrent disease),Cervical cancer (in combination with paclitaxel and cisplatin or topotecan for persistent, recurrent, or metastatic disease),Off-label uses: age-related macular degeneration (intravitreal), hereditary hemorrhagic telangiectasia, ovarian cancer (first-line maintenance), breast cancer (not FDA approved)
1 drop of 1% solution into the affected eye every 2 hours while awake, up to 9 drops per day, for 7-21 days.
5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).
Terminal elimination half-life is approximately 2.5 hours in adults with normal renal function. In patients with renal impairment, half-life may be prolonged, requiring dose adjustment.
Terminal half-life approximately 20 days (range 11–50 days) in patients; supports dosing every 2–3 weeks
Primarily metabolized via thymidine phosphorylase and other nucleoside-metabolizing enzymes; systemic metabolism is minimal due to topical application.
Bevacizumab is primarily metabolized via proteolytic degradation into small peptides and amino acids. No specific metabolic enzymes are involved; it is not metabolized by cytochrome P450 enzymes.
Renal excretion of unchanged drug and metabolites; approximately 70% of a dose is recovered in urine within 24 hours. Biliary/fecal elimination accounts for less than 10%.
Primarily via reticuloendothelial system and proteolytic catabolism; negligible renal excretion (<1% unchanged in urine)
Protein binding is approximately 15-20%, primarily to albumin.
Bound primarily to albumin and other plasma proteins; approximately 95–100% bound (saturable binding to Fc Rn may occur)
Volume of distribution is approximately 0.5 L/kg, indicating distribution into total body water.
Vd approximately 2.9–3.7 L (not weight-normalized; small Vd consistent with large monoclonal antibody confined mainly to plasma and interstitial space)
Systemic bioavailability following ophthalmic administration is minimal (less than 5%) due to low corneal penetration and rapid dilution by tears; not administered orally or parenterally.
Only available as intravenous infusion; bioavailability 100% by IV route; not administered subcutaneously or orally (no bioavailability data for other routes)
No dose adjustment required; negligible systemic absorption following topical ocular administration.
No dose adjustment is recommended for patients with renal impairment; however, be cautious in severe renal impairment (GFR <30 m L/min) due to limited data.
No dose adjustment required; negligible systemic absorption following topical ocular administration.
No specific dose adjustment guidelines exist for hepatic impairment based on Child-Pugh score; use with caution in severe hepatic impairment.
Same as adult dosing: 1 drop of 1% solution into the affected eye every 2 hours while awake, up to 9 drops per day, for 7-21 days.
Safety and efficacy in pediatric patients have not been established; no standard dosing guidelines available.
Same as adult dosing; no specific elderly considerations beyond standard monitoring for ocular effects.
No specific dose adjustment is required for elderly patients; however, monitor for increased incidence of arterial thromboembolic events, hypertension, and proteinuria as seen in clinical trials.
None.
WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE. Gastrointestinal perforations occur in up to 2.4% of patients. Discontinue for perforations, tracheoesophageal fistula, or wound dehiscence. Severe or fatal hemorrhage, including hemoptysis and gastrointestinal bleeding, has occurred; monitor for bleeding.
May cause local irritation, burning, stinging, or edema.,Prolonged use may lead to corneal epithelial toxicity or scarring.,Not for use in herpes simplex virus infections involving the corneal stroma or uveal tract.
Gastrointestinal perforations and fistulae (including tracheoesophageal),Surgery and wound healing complications: do not administer within 28 days of major surgery or until wound is fully healed,Hemorrhage: severe or fatal pulmonary hemorrhage (particularly in squamous NSCLC), gastrointestinal bleeding, and cerebral hemorrhage,Non-gastrointestinal fistula formation (including bronchopleural, biliary, and vaginal),Arterial thromboembolic events (e.g., stroke, myocardial infarction): risk increased in patients ≥65 years of age,Hypertension: monitor blood pressure; may require antihypertensive therapy,Reversible posterior leukoencephalopathy syndrome (RPLS),Proteinuria: monitor urine protein; discontinue if nephrotic syndrome develops,Ovarian failure: may impair fertility in women,Congestive heart failure: increased incidence in patients receiving anthracyclines or with prior chest radiation
Hypersensitivity to trifluridine or any component of the formulation.
Known hypersensitivity to bevacizumab or any components of the formulation,Recent hemoptysis (≥2.5 m L of red blood) within 21 days prior to treatment,Untreated central nervous system metastases (due to risk of bleeding; treat prior to bevacizumab)
No known food interactions. Avoid alcohol if driving due to temporary blurred vision.
No specific food interactions known. No restrictions beyond general dietary advice for cancer patients.
Pregnancy Category C. Animal reproduction studies have shown embryotoxicity and teratogenicity at high doses. No adequate human studies. Risk cannot be ruled out; use only if clearly needed.
Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal impairment, and spontaneous abortion reported. Avoid use unless potential benefit justifies risk.
Excretion in human milk unknown. Caution advised. M/P ratio not established.
No data on excretion in human milk. M/P ratio unknown. Due to potential for adverse effects in nursing infants, breastfeeding is not recommended during therapy and for at least 6 months after last dose.
No pharmacokinetic data in pregnancy; dose adjustment not established. Use usual adult dose only if potential benefit justifies risk.
No formal dose adjustment studies in pregnancy. Increased volume of distribution and clearance may occur, but no dose changes recommended. Use lowest effective dose with careful monitoring.
Trifluridine (VIROPTIC) is a topical antiviral for herpes simplex keratitis. Initiate therapy early; 1 drop q2h while awake (max 9 drops/day) for acute infection, then taper. Avoid prolonged use beyond 21 days to prevent corneal toxicity. Re-evaluate if no improvement after 7 days. Does not treat stromal disease or iritis without epithelial involvement.
Monitor blood pressure closely; hypertension is common. Hold therapy 28 days before elective surgery due to impaired wound healing. Use with caution in patients with cardiovascular disease or history of arterial thromboembolism. Proteinuria monitoring required; urine dipstick at baseline and regularly. Avoid in patients with recent hemoptysis or untreated CNS metastases.
Do not touch dropper tip to eye or any surface to avoid contamination.,Apply exactly as prescribed; do not skip doses or stop early.,Mild stinging or burning is common; report severe pain, vision changes, or worsening redness.,Wash hands before and after use; wait 5 minutes between different eye drops.,Remove contact lenses during treatment and discard if used while infected.,Use separate towel and wash hands frequently to avoid spreading infection.
Report any signs of bleeding, such as unusual bruising, nosebleeds, or blood in urine/stool.,Inform your doctor immediately if you experience severe headache, vision changes, confusion, or seizures (signs of PRES).,Avoid surgery or dental procedures without notifying your oncologist; therapy may need to be paused.,Females of childbearing age must use effective contraception during and for 6 months after treatment.,Do not drive if you experience vision problems or dizziness from therapy.
No interactions on record
No interactions on record
Common clinical questions about VIROPTIC vs AVASTIN, answered by our medical review team.
VIROPTIC is a Antiviral (Ophthalmic) that works by Trifluridine is a fluorinated pyrimidine nucleoside analogue that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase.. AVASTIN is a Antineoplastic (Angiogenesis Inhibitor) that works by Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VIROPTIC and AVASTIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VIROPTIC is: 1 drop of 1% solution into the affected eye every 2 hours while awake, up to 9 drops per day, for 7-21 days.. The standard adult dose of AVASTIN is: 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VIROPTIC and AVASTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VIROPTIC is classified as Category C. Pregnancy Category C. Animal reproduction studies have shown embryotoxicity and teratogenicity at high doses. No adequate human studies. Risk cannot be ruled out; use only if clear. AVASTIN is classified as Category C. Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal imp. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.